Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919163 | 0.88 | SCN9A (0.47) | MAOBPARP10SCN9A | |
| SCHEMBL3971405 | 0.87 | NPC1 (0.56) | MAOBNR4A2PPARAMAOA | |
| SCHEMBL1067948 | 0.87 | MAOB (0.65) | MAOBPARP10NR4A2PPARAMAOA | |
| SCHEMBL13958849 | 0.83 | MAOB (0.57) | MAOBPARP10NR4A2PPARACA12 | |
| SCHEMBL920177 | 0.83 | SCN3A (0.65) | MAOBPARP10SCN9A | |
| SCHEMBL3969644 | 0.79 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL3967573 | 0.79 | PARP15 (0.60) | MAOBPARP10MAOASCN9A | |
| SCHEMBL919293 | 0.79 | SCN9A (0.42) | MAOBMAOASCN9A | |
| SCHEMBL28500733 | 0.78 | MAOB (0.61) | MAOBPARP10NR4A2CA12CA1 | |
| SCHEMBL920257 | 0.78 | FAAH (0.47) | PARP10SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842143-B3 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2009-02-18 | — | — | EP | claimed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | claimed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | claimed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | disclosed |
| US-7709523-B2 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS SPA (IT) | 2010-05-04 | — | — | US | disclosed |
| EP-0842143-B3 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2009-02-18 | — | — | EP | disclosed |
| EP-1585510-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARM SPA (IT) | 2007-12-05 | — | — | EP | disclosed |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-04-13 | — | — | US | disclosed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | disclosed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | disclosed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | disclosed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | disclosed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | AANAT, FAAH, ACHE | MAOB 184/4885PARP10 1504/4885NR4A2 4122/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | MAOB 236/4885PARP10 3049/4885NR4A2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.